key: cord-0930004-qlqinlco authors: Zhao, Hong; Zhang, Chi; Zhu, Qi; Chen, Xianxiang; Chen, Guilin; Sun, Wenjin; Xiao, Zuohan; Du, Weijun; Yao, Jing; Li, Guojun; Ji, Yanhua; Li, Niuniu; Jiang, Yujin; Wang, Ying; Zeng, Qingjin; Li, Wei; Gong, Beilei; Chang, Xianyou; Zhu, Feng; Jiang, Xiufeng; Li, Jiawen; Wu, Zhao; Liu, Yingxia; Peng, Peng; Wang, Guiqiang title: Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial date: 2021-04-21 journal: Int Immunopharmacol DOI: 10.1016/j.intimp.2021.107702 sha: 536e30269ad457bf5cae7b6c13eec3528d27121d doc_id: 930004 cord_uid: qlqinlco Background The clinical characteristics and treatment of patients who tested positive for COVID-19 after recovery remained elusive. Effective antiviral therapy is important for tackling these patients. We assessed the efficacy and safety of favipiravir for treating these patients. Methods This is a multicenter, open-label, randomized controlled trial in SARS-CoV-2 RNA re-positive patients. Patients were randomly assigned in a 2:1 ratio to receive either favipiravir, in addition to standard care, or standard care alone. The primary outcome was time to achieve a consecutive twice (at intervals of more than 24 hours) negative RT-PCR result for SARS-CoV-2 RNA in nasopharyngeal swab and sputum sample. Results Between March 27 and May 9 2020, 55 patients underwent randomization; 36 were assigned to the favipiravir group and 19 were assigned to the control group. Favipiravir group had a significantly shorter time from start of study treatment to negative nasopharyngeal swab and sputum than control group (median 17 vs. 26 days); hazard ratio 2.1 (95% CI [1.1 - 4.0], p=0.038). The proportion of virus shedding in favipiravir group was higher than control group (80.6% [29/36] vs. 52.6% [10/19], p=0.030, respectively). C-reactive protein decreased significantly after treatment in the favipiravir group (p=0.016). The adverse events were generally mild and self-limiting. Conclusion Favipiravir was safe and superior to control in shortening the duration of viral shedding in SARS-CoV-2 RNA recurrent positive after discharge. However, a larger scale and randomized, double-blind, placebo-controlled trial is required to confirm our conclusion. At the end of 2019, a new coronavirus named SARS-CoV-2, has caused an international outbreak of respiratory illness termed COVID-19 [1] . By December 24 2020, COVID-19 had infected more than 70 million people and killed about 1.7 million people worldwide [2] . According to the discharge criteria in China's COVID-19 prevention and treatment guidelines [3] , more and more COVID-19 patients were discharged from hospital and received regular follow-up observation. Nevertheless, it has been reported that SARS-CoV-2 RNA has been re-detected in some recovered patients [4] [5] [6] [7] [8] . Unfortunately, the mechanism of recurrent positive of SARS-CoV-2 was not clear at present. Favipiravir is a new broad-spectrum antiviral drug, which targets RNA-dependent RNA polymerase. On February 13, 2020, favipiravir tablets were approved by China FDA (batch number: 2020L00005) for COVID-19 's clinical trial. Favipiravir has a wide range of antiviral effects, including influenza A and B, viral haemorrhagic fever etc. [9] . In addition, a retrospective study of Ebola virus disease showed that the overall survival rate in the favipiravir group was higher than that in the control group (56.4% [22/39] vs35.3% [30/85], p=0.027) [10] . Experiments on favipiravir showed that it had anti-SARS-CoV-2 activity in vitro, although higher concentrations were required compared with chloroquine or remdesivir [11] . An open-label non-randomized clinical trial has shown that favipiravir can shorten the time of SARS-CoV-2 clearance compared with lopinavir/ritonavir (median 4 day [IQR 2. [5] [6] [7] [8] [9] vs. 11 day [8] [9] [10] [11] [12] [13] P < 0.001). The improvement rate of chest imaging in the favipiravir group was significantly better than that of control group (91.43% vs. 62.22%, P = 0.004) [12] . We designed this clinical trial to verify the efficacy and safety of favipiravir in SARS-CoV-2 RNA recurrent positive after discharge. In this multicenter, randomized controlled trial, we screened patients who tested repositive for SARS-CoV-2 RNA after discharge from 5 hospitals in mainland China. The discharge of COVID-19 patients should meet the following criteria [3] : ①Body temperature returned to normal for at least 3 days. ② Respiratory symptoms significantly improved. ③ Pulmonary imaging showed that acute exudative lesions were significantly absorbed and improved. ④ The SARS-CoV-2 RNA test of respiratory tract samples was negative for two consecutive times (the sampling time was at least 1 day). The trial was done in accordance with the principles of the has been registered at clinicaltrials.gov (NCT04333589) and also available on Trials [13] . From March 27 to May 9, 2020, we screened a total of 67 SARS-CoV-2 RNA recurrent positive after discharge. All patients enrolled in the favipiravir group and the control group should meet the following inclusion and exclusion criteria. The inclusion criteria include: ① Over 18 years of age, both male and female; ②After the first diagnosis and treatment of COVID-19, the SARS-CoV-2 RNA test of respiratory specimens such as sputum or nasopharyngeal swabs, has been negative for two consecutive times (sampling time interval of at least 24 hours), in accordance with China COVID-19 guidelines (7th Edition), discharged; ③ During screening visit (follow-up after discharge), the SARS-CoV-2 RNA test of COVID-19 is positive in any one of the following samples: sputum, nasopharyngeal swabs, blood, feces or other specimens. Regardless of whether or not they had symptoms and the severity of symptoms; ④ Volunteer to participate in the research and sign the Informed Consent Form. Key exclusion criteria included: ① Allergic to favipiravir; ② Pregnant or lactating women; ③The researchers considered the patient was not suitable to participate in this clinical trial. Patients were randomly assigned to either the favipiravir group or the control group, in the ratio of 2:1, by simple randomization with no stratification. Randomized treatment was open-label. Patients were assigned to a serial number by the study coordinator. Each serial number was linked to a computer-generated randomization list assigning the antiviral treatment regimens. The study medications were dispensed by the hospital pharmacy and then to the patients by the medical ward nurses. The use of favipiravir was 1600 mg (bid) on the first day, and 600 mg (bid) from the 2nd day to the 7th day, orally. After that, the researchers decided whether to continue favipiravir according to the patient's condition, but no more than 14 days of treatment. Patients assigned to the control group received drugs other than favipiravir and treatment according to the needs of the disease. All enrolled patients had to have laboratory confirmed SARS-CoV-2 infection by RT-PCR in the nasopharyngeal swab. In order to avoid being mistakenly taken as saliva when taking sputum samples, sputum samples were taken from the respiratory tract samples after deep cough. The primary outcome was time to achieve a consecutive twice (at intervals of more than 24 hours) negative RT-PCR result for SARS-CoV-2 RNA in nasopharyngeal swab and sputum sample. The secondary outcomes were the changes of blood routine and CRP (C-reactive protein); the count and proportion of T lymphocyte subsets in peripheral blood and the changes of cytokines. In addition, we also analyzed the relationship between the antibody titer and the SARS-CoV-2 RNA re-negative time. The safety end point is the frequency of adverse events in each group. Quantitative variables were expressed as the median and range (or mean with standard deviation). Categorical variables were demonstrated with number and percentage. The t test (paired and non-paired) or Kruskal-Wallis analysis were used to compare continuous variables, and Chi-square or Fisher's exact tests were used to categorical variables. SARS-CoV-2 positive rate between favipiravir group and control group curves were analyzed by log-rank (Mantel-Cox) test. The patient's sample size was calculated based on previous studies by Hung and colleagues [14] . Our hypothesis was that there may be a 5-day difference in the duration of SARS-CoV-2 between the favipiravir group and the control group, which meant that the sample size of a total of 48 patients (32 in favipiravir group and 16 in control group) was needed (with a power of 90% for a significance level of 5% with a two-tailed test). The p<0.05 was considered to be statistically significant. Statistical analysis was conducted with R (version 3.6.2). From March 27 to May 9, 2020, 67 patients were screened, of whom 55 (36 in favipiravir group and 19 in control group) were eligible ( Figure 1 ). The median age of study patients was 60 years (ranging from 28 to 79); sex distribution was 16 (44.4%) men versus 20 (55.6%) women in the favipiravir group and 10 (52.6%) versus 9 (47.4%) in the control group. There was no significant difference in patients' demographic and clinical characteristics before treatment between two groups ( have ever used glucocorticoid. The duration of the first SARS-CoV-2 RNA positive was 28.2 ± 14.8 days (favipiravir group and control group were 28.3 ± 16.6 and 27.8 ± 11.3 days, respectively), of which the shortest was 5 days and the longest was 86 days. The time from the first SARS-CoV-2 RNA negative (two consecutive times) to this repositive was 20.6 ± 17.4 days (favipiravir group and control group were 22.2 ± 19.3 and 17.9 ± 13.9 days, respectively). All the patients' vital signs were stable (not shown). Most of the patients (69.1% [38/55]) were without clinical symptoms. Cough was the most common among these symptomatic patients, accounting for only 16.4% (9/55). Other clinical symptoms such as fever, diarrhea and chest tightness were shown in Table 2 . As with the first COVID-19 onset, the clinical classification was mainly the moderate type, regardless of the favipiravir group or the control group. The white blood cell count in these re-positive patients were in the normal range (reference values were shown in Table S2 ). One patient in the favipiravir group had chronic lymphoblastic leukemia, so his blood routine was quite different from the other patients. The median lymphocyte count (1.74 vs. 1.88×10 9 /L) and percentage (28.6% vs. 31.8%) were at the lower limit of the normal value in both the favipiravir group and the control group (Table 2) . For the primary endpoint of time from start of study treatment to negative nasopharyngeal swab and sputum, the favipiravir group had a significantly shorter median time (17 days) than the control group (26 days; hazard ratio 2.1 [95% CI 1.1 -4.0], p=0.038; Figure 2 ). At the end of this clinical trial (30 days), the proportion of SARS-CoV-2 RNA PCR turning negative in the favipiravir group was much higher than control group (80.6% [29/36] vs. 52.6% [10/19], p=0.030, respectively). No death was reported in both groups. After treatment, CRP decreased significantly from baseline in favipiravir group (4.0±9.1 to 1.5±2.1 mg/L, p=0.016, Figure 3B ), while the control group did not change significantly (2.0±2.8 to 1.8±2.7 mg/L, p=0.710). In favipiravir group, CRP decreased significantly from baseline in patients with negative RNA after therapy (2.9±4.7 to 1.5±2.3 mg/L, p=0.005). Monocyte count also showed a significant decrease after therapy in the favipiravir group (0.45±0.17 to 0.38±0.12×10^9/L, p = 0.020, Figure 3G ). Figure 4 shows the improvement of clinical symptoms in the favipiravir group and the control group before and after treatment. Before treatment, there seemed to be more clinical symptoms in the control group, but there was no statistical difference between them (Table 1 ). Figure 4A shows the clinical symptoms of the favipiravir group. After treatment, almost all the clinical symptoms, including fever, disappeared, and only one patient with cough. In the control group, cough was relieved in only half of the patients(3/6), and other clinical symptoms are shown in Figure 4B . Because there are few people with clinical symptoms, we only give a simple description. The CD3+ T cell and CD8 + T cell counts decreased within the first 7 days and then increased in the favipiravir group, in contrast a continuous decrease trend in the control group ( Figure 5B and Figure 5F ). The CD4+ T cell count did not show an upward trend in both the control group and the favipiravir group ( Figure 5D , In favipiravir group, IL-8 (mean value 653.7 to 95.3U/L, p=0.007, Figure S1F ) and TNF-β (mean value 2.8 to 2.2 U/L, p=0.013, Figure S1M ) had a significant decline after treatment. IL-1β (mean value 2.6 to 1.3 U/L, p=0.095, Figure S1A ) and IL-5 (mean value 3.3 to 2.2 U/L, p=0.056, Figure S1D ) also decreased in values although had no statistical difference. In control group, only IL-1β had an obvious reducing compared with its baseline level (mean value 1.9 to 0.9 U/L, p=0.018, Figure S1A ). We detected anti-SARS-CoV-2 antibodies in 32 patients (the rest 23 patients refuse to be tested). During the entire study, the IgG antibodies of all tested patients were positive, regardless of whether the SARS-CoV-2 RNA was positive. Meanwhile, only 37.5% Figure S2B ). A total of 19 adverse events occurred in this clinical trial. There were 12 in favipiravir group and 7 in control group. Elevated transaminase (ALT and AST) was the most common in both the favipiravir group and the control group. Hyperuricemia, diarrhea, nausea and other adverse reactions were also reported, as detailed in Table S3 . No serious adverse effects occurred in this clinical trial, and the aforementioned adverse reactions were alleviated during subsequent follow-up. In this multicenter, randomized clinical trial of patients with SARS-CoV-2 RNA repositive after discharged, patients who received favipiravir had faster virus clearance than control group. CRP decreased more significantly in favipiravir group. The adverse events were generally mild and self-limiting in favipiravir group. There were many drugs that may be effective against SARS-COV-2, such as remdesivir, lopinavir-ritonavir, Umifenovir, chloroquine, hydroxychloroquine, ribavirin, interferon-α/γ [16] . We also have several unavoidable limitations in this clinical trial. First of all, due to the limited number of recurrent positive patients, the sample size of this study needs to be expanded. Secondly, the trial was not blinded, so it is possible that knowledge of the treatment assignment might have influenced clinical decision-making. Thirdly, we followed up all the patients for only 30 days, and it is not clear whether these patients will return to positive again. Fourth, because the EDC system records only the qualitative data of PCR results, we have not been able to obtain the Ct value of the dynamic changes of SARS-CoV-2 RNA in patients. Fifth, the presence of few symptomatic patients in this study, and only mild symptoms, prevents us from demonstrating a clear clinical benefit of favipiravir. Sixth, hospital admission is mandatory in PCR positive patients in China, and discharge is not allowed meanwhile PCR is still positive, but these measures are not followed worldwide, so the benefits of treatment may not be widespread in other settings. Favipiravir can significantly short SARS-CoV-2 positive time of patients whose RNA re-positive after discharge; increase the chance of virus negative conversion and have better safety. However, a larger scale and randomized, double-blind, placebo-controlled trial is required to fully assess the efficacy and safety of favipiravir in patients with SARS-CoV-2 recurrent positive after discharge. Wuxi Fifth People's Hospital) and has been registered in ClinicalTrials.gov (NCT04333589). All patients signed the informed consent form. Availability of data and materials: All data generated or analyzed during this study were included in this article (and its supplementary information files). The shaded areas represent pointwise 95% confidence intervals. 3 With a history of at least one chronic disease or malignant tumor. 4 The "SARS-CoV-2 RNA positive duration" refers to the time from the first positive detection of SARS-CoV-2 RNA to two consecutive nasopharyngeal swabs negative. Two patients were unable to get "SARS-CoV-2 RNA positive duration" data. 5 The "Re-Positive Interval" refers to the time from two consecutive nasopharyngeal swabs negative to this recurrent positive interval. Six patients were unable to get "Re-Positive Interval" data. SPD, SARS-CoV-2 RNA Positive Duration; CHD, Coronary heart disease; CLD, Chronic Liver Disease GGT glutamyl transpeptidase; Cr creatinine; UA uric acid. One patient in the favipiravir group was chronic lymphocytic leukemia, with a lymphocyte percentage as high as 82.8%, so the patient was excluded from the analysis. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine Diagnosis and treatment protocol for novel coronavirus pneumonia Positive RT-PCR Test Results in Patients Recovered From COVID-19 Assessment of patients who tested positive for COVID-19 after recovery Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19 Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chinese medical journal Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test an antiviral for COVID-19? Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering The Mechanism and Clinical Outcome of patients with Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Fangcang shelter hospitals: a novel concept for responding to public health emergencies Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof) Favipiravir can significantly shorten SARS-CoV-2 RNA positive duration Competing interests: All authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Co.Ltd for its participation in data checking and collation.Competing interests: All authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.